Physicians' Academy for Cardiovascular Education
Prof. Sattar shares his thoughts on why high triglycerides reflect ectopic fat and how this relationship may help to motivate patients to sustain weight improvements and lower CV and diabetes risks.
NICE in the UK has published a final guidance on recommendation for use of icosapent ethyl in adult statin-treated patients with elevated triglycerides, well-controlled LDL-c and established CVD.
The REDUCE-IT trial showed that treatment with icosapent ethyl is effective in patients receiving a statin who meet certain biochemical criteria. The CAC score may help to identify patients who would benefit most from this treatment.
The National Institute for Health and Care Excellence (NICE) has published a final draft guidance which recommends use of icosapent ethyl in adults with CVD, statin-controlled LDL-c levels and elevated triglycerides.
EAS 2022 The ANGPLT3/8 complex inhibits LPL 100-fold more potently than ANGPLT3 alone, making this complex an attractive target for CVD prevention in subjects with mixed hyperlipidemia.
EAS 2022 An ASO targeting ANGPTL3 mRNA, significantly reduced VLDL and remnant cholesterol, but had side effects at higher doses. What could be next steps in this research area?
Watch the videos in this series and learn about icosapent ethyl in relation to CV risk and its potential mechanisms of action!
A study demonstrated that traditional CV factors (BMI, SBP, total cholesterol level, triglyceride level, and smoking) in childhood are associated with CV events during adulthood.
Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.
Does the type or lipid content of apoB-containing lipoprotein carry any additional risk of MI beyond the total number of apoB-containing lipoproteins?
Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.
